Carmignac Portfolio Patrimoine Europe: Letter from the Fund Manager
Carmignac Portfolio Patrimoine Europe A EUR Acc lost -5.70% in the second quarter of 2022, outperforming the -6.55% drop in its reference indicator¹.
Quarterly Performance Review
In the second quarter, the war and the commodity-price shock sent an inflationary impulse to developed economies. The latter, already facing post-Covid overheating, have also been affected by China's zero-Covid policy, which has put further strain on supply chains. Accordingly, the timing of peak inflation kept being pushed back, prompting a sharp response from central banks – first and foremost the Fed. As the inflation outlook has evolved, developed-world central banks have pursued their increasingly hawkish monetary policies. Towards the end of the period, the rhetoric changed as market participants became increasingly concerned about growth. This is particularly true in Europe, where at the dawn of its policy normalisation, the ECB is faced with a dilemma: how to combat ever-rising inflation without slowing the economic growth that has already been hit by the war in Ukraine and the situation in China?
This confluence of events has affected both equity and bond markets which were, once again this quarter, primarily driven by monetary policy decisions and macroeconomic data. Equity valuations have therefore been revised downward as interest rates moved higher to reflect central bankers' normalization policies. Despite an overall prudent exposure, our Fund has not been able to fully mitigate the massive decline in asset prices and recorded a negative performance over the period.
We started the quarter with a very defensive approach, characterized by a low equity exposure, reduced credit investments and a high level of liquidity. We kept this positioning during the period, and it was efficient in compensating most of the equity losses. However, it wasn’t enough to mitigate the widening of credit spreads, which suffered the double blow of both higher interest rates and increased credit risk.
In our equity book, both our stock selection and our hedges helped the Fund to attenuate the blow. Our positioning toward quality growth names did well in relative terms, helped by our Q1 adjustments, which made our equity book more defensive. One example of this is the performance of our main sector weighting – healthcare – which made a positive contribution to returns over the quarter, while European markets were down by more than 10%. The industry leaders, such as Novo Nordisk and Sanofi, have held up well and so have more innovative companies like Argenx. However, the key issue in this environment was risk management. In this regard, the sector hedges we implemented throughout the period worked well, especially those on technology indices (Stoxx 600 Tech, Nasdaq). They allowed us to mitigate the growth bias in the portfolio and to benefit from the rise in interest rates and the impact on the valuations of technology companies.
On the fixed income side, in addition to our credit book, volatility on interest rates has been unprecedented and dragged down performance. In June, we experienced episodes of high volatility not seen for years. After fears of persistently high inflation, market participants appeared to shift their focus to fears of slowing growth. As interest rates fell to deal with this new landscape, we maintained our view that inflation will be the main concern in the coming weeks. As a result, our short positions on rates weighed on the Fund's performance, but we hold to our view that inflation will be the ECB's main issue over the coming months.
Our Positioning and Outlook
Escalating concerns that central banks' efforts to tackle inflation by hiking rates will trigger a global slowdown was the main topic in the markets at quarter end. The key question for us is not whether they can tackle inflation without leading developed economies into a recession, but rather how hard the landing will be. The impact of a recession on the market could be very different from what we have seen in recent months.
On the equity side, after valuations suffered from the rising interest rates, corporate earnings should be the driving force behind stock markets going forward. While they’ve shown resilience so far, they are likely to come under pressure since the impact of rising costs is not yet reflected in companies’ margins. We therefore believe that a focus on quality growth companies with high profitability and that reinvest in future growth should support performance, at least relatively. Over the period, we continued to rotate our portfolio by reducing the weighting of cyclical companies (such as Kingspan, Schneider and Epiroc) and increasing the weighting of companies in more defensive sectors, particularly healthcare and corporate services (SAP, Edenred). We also believe that the de-rating in some high-quality names makes them very attractive and provides excellent opportunities to deploy our cash in the coming months. However, stocks still have not reached a capitulation point and investors’ mood may be shifting from fear of missing out to fear of holding on. In this regard, we have maintained our hedging on equity markets and therefore start the third quarter with a net exposure close to 0%.
On the fixed income side, the situation might be different. Valuations suggest a somewhat more constructive stance to credit markets, which seem to have integrated both tighter monetary policies and higher recession risks. Underneath the surface, this has provided various specific opportunities which we are steadily gaining exposure to, while still covering our overall market risk. On the sovereign front, we stay cautious on Europe given the ECB’s intention to proceed with monetary tightening by all means, as expressed in its willingness to address fragmentation concerns – i.e. keeping a lid on any significant widening in eurozone spreads. However, we expect the volatility to stay high. With this in mind, we are actively managing the modified duration of the fund on a more tactical basis. But, underneath this cautiousness, we are preparing to redeploy our substantial pool of liquidity into the various asset classes at our disposal and sow the seeds of future performance drivers.
Carmignac Portfolio Patrimoine Europe
Fund built to take advantage of Europe’s many sectors and opportunities.Discover the fund pageCarmignac Portfolio Patrimoine Europe A EUR Acc
- Recommended minimum investment horizon
- 3 years
- Risk indicator*
- 3/7
- SFDR - Fund Classification**
- Article 8
*Risk Scale from the KID (Key Information Document). Risk 1 does not mean a risk-free investment. This indicator may change over time. **The Sustainable Finance Disclosure Regulation (SFDR) 2019/2088 is a European regulation that requires asset managers to classify their funds as either 'Article 8' funds, which promote environmental and social characteristics, 'Article 9' funds, which make sustainable investments with measurable objectives, or 'Article 6' funds, which do not necessarily have a sustainability objective. For more information please refer to https://eur-lex.europa.eu/eli/reg/2019/2088/oj.
Main risks of the fund
Performance
| Carmignac Portfolio Patrimoine Europe | -4.8 | 18.7 | 13.9 | 9.5 | -12.7 | 2.1 |
| Reference Indicator | -4.8 | 16.4 | 2.4 | 10.2 | -11.0 | 9.5 |
| Carmignac Portfolio Patrimoine Europe | - 1.6 % | + 4.0 % | + 4.3 % |
| Reference Indicator | + 1.1 % | + 3.1 % | + 3.6 % |
Source: Carmignac at Oct 31, 2024.
Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor).
| 1.79% | Yes | 4% |
Related articles
Carmignac strengthens the Patrimoine Management team and enhances Senior Management
Marketing communication. Please refer to the KID/KIID, prospectus of the fund before making any final investment decisions. This document is intended for professional clients.
This material may not be reproduced, in whole or in part, without prior authorisation from the Management Company. This material does not constitute a subscription offer, nor does it constitute investment advice. This material is not intended to provide, and should not be relied on for, accounting, legal or tax advice. This material has been provided to you for informational purposes only and may not be relied upon by you in evaluating the merits of investing in any securities or interests referred to herein or for any other purposes. The information contained in this material may be partial information and may be modified without prior notice. They are expressed as of the date of writing and are derived from proprietary and non-proprietary sources deemed by Carmignac to be reliable, are not necessarily all-inclusive and are not guaranteed as to accuracy. As such, no warranty of accuracy or reliability is given and no responsibility arising in any other way for errors and omissions (including responsibility to any person by reason of negligence) is accepted by Carmignac, its officers, employees or agents.
Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.
Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice. The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.
Morningstar Rating™ : © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
Access to the Funds may be subject to restrictions regarding certain persons or countries. This material is not directed to any person in any jurisdiction where (by reason of that person’s nationality, residence or otherwise) the material or availability of this material is prohibited. Persons in respect of whom such prohibitions apply must not access this material. Taxation depends on the situation of the individual. The Funds are not registered for retail distribution in Asia, in Japan, in North America, nor are they registered in South America. Carmignac Funds are registered in Singapore as restricted foreign scheme (for professional clients only). The Funds have not been registered under the US Securities Act of 1933. The Funds may not be offered or sold, directly or indirectly, for the benefit or on behalf of a «U.S. person», according to the definition of the US Regulation S and FATCA.
The risks, fees and ongoing charges are described in the KID (Key Information Document). The KID must be made available to the subscriber prior to subscription. The subscriber must read the KID. Investors may lose some or all their capital, as the capital in the funds are not guaranteed. The Funds present a risk of loss of capital.
The Funds’ prospectus, KIDs, NAVs and annual reports are available at www.carmignac.com, or upon request to the Management Carmignac Portfolio refers to the sub-funds of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive. The French investment funds (fonds communs de placement or FCP) are common funds in contractual form conforming to the UCITS or AIFM Directive under French law.
In France, Luxembourg, Sweden: The risks, fees and ongoing charges are described in the KID (Key Information Document). The KID must be made available to the subscriber prior to subscription. The subscriber must read the KID. Investors may lose some or all their capital, as the capital in the funds are not guaranteed. The Funds present a risk of loss of capital. The Funds’ prospectus, KIDs, NAV and annual reports are available at www.carmignac.com, or upon request to the Management.
In the United Kingdom: the Funds’ respective prospectuses, KIIDs and annual reports are available at www.carmignac.co.uk, or upon request to the Management Company, or for the French Funds, at the offices of the Facilities Agent at BNP PARIBAS SECURITIES SERVICES, operating through its branch in London: 55 Moorgate, London EC2R. This document was prepared by Carmignac Gestion, Carmignac Gestion Luxembourg or Carmignac UK Ltd. FP Carmignac ICVC (the “Company”) is an Investment Company with variable capital incorporated in England and Wales under registered number 839620 and is authorised by the FCA with effect from 4 April 2019 and launched on 15 May 2019. FundRock Partners Limited is the Authorised Corporate Director (the “ACD”) of the Company and is authorised and regulated by the FCA. Registered Office: Hamilton Centre, Rodney Way, Chelmsford, Essex, CM1 3BY, UK; Registered in England and Wales with number 4162989. Carmignac Gestion Luxembourg SA has been appointed as the Investment Manager and distributor in respect of the Company. Carmignac UK Ltd (Registered in England and Wales with number 14162894) has been appointed as a sub-Investment Manager of the Company and is authorised and regulated by the Financial Conduct Authority with FRN:984288.
In Switzerland: the prospectus, KIDs and annual report are available at www.carmignac.ch, or through our representative in Switzerland, CACEIS (Switzerland), S.A., Route de Signy 35, CH-1260 Nyon. The paying agent is CACEIS Bank, Montrouge, Nyon Branch / Switzerland, Route de Signy 35, 1260 Nyon.
The Management Company can cease promotion in your country anytime.
Investors have access to a summary of their rights in English on the following links: UK ; Switzerland ; France ; Luxembourg ; Sweden.